The Effect of Resistive Exercise on Forearm Blood Flow and Tissue Oxygenation Among Breast Cancer Survivors With or at Risk for Breast Cancer-related Lymphoedema (BCRL)

Overview

The purpose of the study is to evaluate the effect of resistive exercise on forearm blood flow and tissue oxygenation among breast cancer survivors with or at risk for breast cancer-related lymphoedema (BCRL).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Single (Investigator)
  • Study Primary Completion Date: August 2017

Detailed Description

160 subjects who have a diagnosis of breast cancer , 80 with and 80 without BCRL, will be recruited. Eligible subjects are Chinese ethnicity female breast cancer survivors, aged younger than 70 years old and body mass index less than 30kg/m2, remained disease free with a clinical diagnosis of stable BCRL and without BCRL. Subjects will be excluded if they have bilateral or unstable BCRL, defined as significant changes to the arm or receiving intensive therapy (i.e. decongestive therapy or antibiotics for infection) within the past 3 months, or musculoskeletal, cardiovascular and/ or neurological disorders that could inhibit them from exercising. Primary outcomes include brachial artery blood flow measured by a Doppler ultrasound device and tissue oxygenation measured by near-infrared spectroscopy (NIRS). Additional outcomes and measures include arm circumference measurement, bioelectrical impedance spectroscopy, self-reported lymphoedema symptoms survey, handgrip dynamometer strength testing, upper limb range of motion measurements and quality of life measures using Functional Assessment of Cancer Therapy-Breast Cancer subscale (FACT-B) questionnaire will be obtained. All outcomes measures will be assessed on both affected and contralateral unaffected arms of all subjects at pre-exercise, immediately post-exercise and 3-month after exercise. Comparison of the baseline measurements between breast cancer survivors with and without BCRL will be obtained. Subjects will be randomly assigned by computer programme to exercise group and control group. Randomization will be stratified by whether axillary dissection and/ or axilla radiotherapy was given or not. The exercise group will receive supervised resistive exercise programme. Subjects in the exercise group will attend small group-based exercise sessions twice a week for 8 weeks supervised by physiotherapists. The duration of each exercise session will last for approximately 1 hour. Prior to resistive exercises, the subjects will perform warm up with movements of large joints and shoulder girdle for 15 minutes. Resistive exercises will focus on the major muscle groups in the upper body. Loading of resistive exercises will be prescribed and progressed according to individual capacity reaching a level of moderate to high loading (6 -12 repetition maximum). The subjects will also be instructed to perform stretching exercises specific to the muscle groups trained after the session. Symptoms responses will be monitored using self-reported lymphoedema symptoms survey before and after each exercise session. Rate of perceived exertion will also be recorded immediately after each exercise session.

Interventions

  • Other: Exercise training
    • 8-week resistive exercise training

Arms, Groups and Cohorts

  • Experimental: Exercise Group
    • The exercise group will receive a supervised resistive exercise training. Subjects in the exercise group will attend small group-based exercise sessions twice a week for 8 weeks supervised by physiotherapists.
  • No Intervention: Control Group
    • The control group will receive no exercise training and continue to receive standard medical care.

Clinical Trial Outcome Measures

Primary Measures

  • Brachial artery blood flow
    • Time Frame: 20 weeks
    • Measured by a Doppler ultrasonic device with a linear probe
  • Tissue oxygenation
    • Time Frame: 20 weeks
    • Measured by Near-infrared spectroscopy

Secondary Measures

  • Arm circumference measurement
    • Time Frame: 20 weeks
    • Measured by tape measure at 10cm-interval from the ulnar styloid process
  • Extent of lymphoedema
    • Time Frame: 20 weeks
    • Measured by bioelectrical impedance spectroscopy
  • Self-reported lymphoedema symptoms survey
    • Time Frame: 20 weeks
  • Hand grip strength
    • Time Frame: 20 weeks
    • Measured by hand grip dynamometer
  • Upper limb range of motion measurement
    • Time Frame: 20 weeks
    • Measured shoulder range of motion with standard goniometer
  • Quality of life measures
    • Time Frame: 20 weeks
    • Measured using Functional Assessment of Cancer Therapy – Breast Cancer Subscale (FACT-B) Questionnaire

Participating in This Clinical Trial

Inclusion Criteria

  • female breast cancer survivors – remained disease free, as defined by unremarkable clinical examination within recent 6 months, with a clinical diagnosis of stable lymphoedema and without lymphedema. Exclusion Criteria:

  • active breast cancer – have bilateral lymphedema or unstable lymphedema – have musculoskeletal, cardiovascular and/ or neurological disorders that could inhibit them from exercising.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Hong Kong Polytechnic University
  • Collaborator
    • Queen Elizabeth Hospital, Hong Kong
  • Provider of Information About this Clinical Study
    • Principal Investigator: Rufina Lau, Clinical Associate – The Hong Kong Polytechnic University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.